The Woodlands, TX, and St. Louis, MO, March 14, 2024 – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies. [Read more…]
Deverra Therapeutics Granted FDA Regenerative Medicine Advanced Therapy and Orphan Drug Designations for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia
Designations Validate Preliminary Data and Enhances Ability to Offer Dilanubicel to Cancer Patients
SEATTLE, WA, March 19, 2024 – Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT)designation to its lead candidate (dilanubicel) for use in first-line treatment for acute myeloid leukemia (AML). [Read more…]
Asgard Therapeutics Snags €30M to Develop In Vivo Direct Cell Reprogramming Technologies for Cancer
€30M Series A financing will advance a novel, off-the-shelf gene therapy (AT-108) that directly reprograms tumor cells into antigen-presenting dendritic cells.
Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and potent anti-cancer immune responses.
Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
Novo Holdings to Acquire the CDMO Catalent for a Staggering $16.5 Billion Enterprise Value
Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024
COPENHAGEN, Denmark and SOMERSET, N.J. – February 5, 2024– Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, announced that they entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. [Read more…]
2024 HEALinc Future Health Summit to Convene Experts in Longevity and Regenerative Health
Over April 28-30th, 2024, on Paradise Island in The Bahamas, the 2024 HEALinc Future Health Summit will be convening experts from across the fields of longevity, cellular medicine, and regenerative health. The event will bring together the world’s top scientists, investors, healthcare providers, longevity tech companies, and stem cell companies. By attending, you will be positioned to learn about cutting-edge future health medicines and technologies that can support peak performance at any age. [Read more…]
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 63
- Next Page »